Page 6,526«..1020..6,5256,5266,5276,528..6,5406,550..»

Drugs that lower blood pressure may boost lip cancer risk

Posted: Published on September 11th, 2012

ByMyHealthNewsDaily Staff Some drugs that treat high blood pressure may increase the risk of lip cancer, a new study suggests. In the study, people who took thehigh blood pressuredrug hydrochlorothiazide for five years or more were four times more likely to develop lip cancer, compared with those who did not take the drug. The study included only Caucasian people. Hydrochlorothiazide is a photosensitizing drug, meaning it can increase a person's sensitivity to sunlight. People who take photosensitizing drugs may burn more easily, or develop rashes upon sunlight exposure. Previous studies have linked hydrochlorothiazide and an increased risk of certainskin cancers. Other photosensitizing drugs examined in the study, including one called nifedipine, increased the risk of lip cancer more than twofold in whites. The findings held even after the researchers took into account study participants' smoking, a factor that increases the risk of lip cancer. Lip cancer is rare (there are about 0.7 cases per 100,000 people per year in the United States), and the benefits of high blood pressure drugs generally outweigh the increased risk of this particular cancer, the researchers said. "However, physicians prescribing photosensitizing drugs should ascertain whether patients are at high risk of lip cancer because of … Continue reading →

Posted in Drugs | Comments Off on Drugs that lower blood pressure may boost lip cancer risk

Global Ovarian Cancer Drugs Market 2011-2015

Posted: Published on September 11th, 2012

NEW YORK, Sept. 10, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Global Ovarian Cancer Drugs Market 2011-2015 http://www.reportlinker.com/p0962688/Global-Ovarian-Cancer-Drugs-Market-2011-2015.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication TechNavio's analysts forecast the Global Ovarian Cancer Drugs market to grow at a CAGR of 13.1 percent over the period 2011-2015. One of the key factors contributing to this market growth is the increasing prevalence of ovarian cancer. The Global Ovarian Cancer Drugs market has also been witnessing the trend of the use of combination therapies for the treatment of ovarian cancer. However, patent expiration of key drugs could pose a challenge to the growth of this market. TechNavio's report, the Global Ovarian Cancer Drugs Market 2011-2015, has been prepared based on an in-depth analysis of the market with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key vendors dominating this market space include Eli Lilly and Co., GlaxoSmithKline plc, Bristol Myers Squibb Co., and Roche Pharmaceuticals. Other vendors mentioned in the report are Johnson & Johnson, Amgen … Continue reading →

Posted in Drugs | Comments Off on Global Ovarian Cancer Drugs Market 2011-2015

Pharmacy School Implements Brown Bag Series as A Part of its New Research Visioning Plan

Posted: Published on September 11th, 2012

Jon Haywood The School of Pharmacy kicked off its first of many Brown Bag Discussions on Sept. 5 in the Thad Cochran Research Center. Nearly 30 talented research scientists and faculty members from both the Jackson and Oxford campuses came together to discuss how to improve, synergize and streamline their areas of research. Our aim is to take four targeted research areas and organize a Brown Bag series around each one of those (in order to) make other investigators and faculty members aware of the strengths that we have, said Dr. Larry Walker, leader of the first Brown Bag discussion and the director of the National Center of Natural Products Research. The four areas that these discussions will target are cancer, cardiometabolic disorders, neuroscience/drugs of abuse and infectious diseases. The Brown Bag series will greatly benefit the Universitys faculty, staff and research scientists. (The discussions) will facilitate the development of new collaborations. It will help scientists gain a better understanding of what their colleagues are doing, stated Dr. Steven Cutler, director of the Center of Research Excellence in Natural Products Neuroscience and another facilitator of the discussions. This series will not only serve faculty, but the students as well. Our … Continue reading →

Posted in Pharmacy | Comments Off on Pharmacy School Implements Brown Bag Series as A Part of its New Research Visioning Plan

Pharmacy Burglars in Brenham Caught on Camera Stealing Pain Pills

Posted: Published on September 11th, 2012

Two thieves were caught on camera during a smash and grab burglary at a Walgreens Pharmacy in Brenham. It happened just before 2:30 Friday morning, and police say the suspects got away with a trash bag full of prescription pain pills. It took several attempts but after three minutes -- not one, but two crooks successfully shattered their window of opportunity. On Friday at approximately 2:26 a.m., surveillance footage from a Walgreen's in Brenham captures two African American men climbing through the pharmacy drive-thru window. The suspects were in and out in approximately 42 seconds. Brenham Police Corporal and Public Information Officer Chris Jackson tells News 3, It would appear they [suspects] knew where they were going and what they were doing." You can see the first suspect crawling through the broken window; once on the ground he darts straight to the second aisle. He then turns around and runs back to the window to grab a black trash bag from his accomplice. The suspect runs back to the aisle, and according to police, steals 18 bottles of hydrocodone. The two then take off before police arrive on scene. While Brenham Police say it's the first time this pharmacy has … Continue reading →

Posted in Pharmacy | Comments Off on Pharmacy Burglars in Brenham Caught on Camera Stealing Pain Pills

Researchers Reveal a Chemotherapy-Resistant Cancer Stem Cell as the "Achilles' Heel" of Cancer

Posted: Published on September 10th, 2012

Newswise Scientists at Mount Sinai School of Medicine have discovered a subpopulation of cells that display cancer stem cell properties and resistance to chemotherapy, and participate in tumor progression. This breakthrough could lead to the development of new tests for early cancer diagnosis, prognostic tests, and innovative therapeutic strategies, as reported in Cancer Cell. Resistance to chemotherapy is a frequent and devastating phenomenon that occurs in cancer patients during certain treatments. Unfortunately, tumors that initially respond to chemotherapy eventually become resistant to it, contributing to tumor progression and death. The study reveals that these new cancer stem cells, which have not been differentiated into more specific cell types, are capable of multiplying despite being exposed to chemotherapy, while differentiated cells die. Led by Carlos Cordon-Cardo, MD, PhD, Chair of Pathology, and Josep Domingo-Domenech, MD, PhD, Assistant Professor of Pathology at Mount Sinai, the research team generated cellular models of drug resistance by treating prostate tumor cell lines with increasing doses of the common chemotherapy drugs, including docetaxel. They identified a cell population expressing markers of embryonic development. In addition, these cells displayed cancer stem cell functions, including the capacity to initiate tumor cell growth. Next, the team evaluated human tissue … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on Researchers Reveal a Chemotherapy-Resistant Cancer Stem Cell as the "Achilles' Heel" of Cancer

Researchers reveal a chemo-resistant cancer stem cell as cancer's 'Achilles' heel'

Posted: Published on September 10th, 2012

Public release date: 10-Sep-2012 [ | E-mail | Share ] Contact: Mount Sinai Press Office newsmedia@mssm.edu 212-241-9200 The Mount Sinai Hospital / Mount Sinai School of Medicine Scientists at Mount Sinai School of Medicine have discovered a subpopulation of cells that display cancer stem cell properties and resistance to chemotherapy, and participate in tumor progression. This breakthrough could lead to the development of new tests for early cancer diagnosis, prognostic tests, and innovative therapeutic strategies, as reported in Cancer Cell. Resistance to chemotherapy is a frequent and devastating phenomenon that occurs in cancer patients during certain treatments. Unfortunately, tumors that initially respond to chemotherapy eventually become resistant to it, contributing to tumor progression and death. The study reveals that these new cancer "stem" cells, which have not been differentiated into more specific cell types, are capable of multiplying despite being exposed to chemotherapy, while differentiated cells die. Led by Carlos Cordon-Cardo, MD, PhD, Chair of Pathology, and Josep Domingo-Domenech, MD, PhD, Assistant Professor of Pathology at Mount Sinai, the research team generated cellular models of drug resistance by treating prostate tumor cell lines with increasing doses of the common chemotherapy drugs, including docetaxel. They identified a cell population expressing markers … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on Researchers reveal a chemo-resistant cancer stem cell as cancer's 'Achilles' heel'

Arroyo undergoes 4th stem cell treatment

Posted: Published on September 10th, 2012

By Leila B. Salaverria Philippine Daily Inquirer Former President and now Pampanga Rep. Gloria Macapagal Arroyo: Stem cell treatment MANILA, PhilippinesLike her predecessor, former President and Pampanga lawmaker Gloria Macapagal Arroyo has turned to stem cell therapy in an effort to improve her health. Arroyo said in her official Twitter account that she would have her fourth stem cell intravenous treatment with her alternative medicine doctor on Monday. Arroyo said her treatment would involve cultured stem cells, and it would be much more modest in price than the one coming from sheep or ones own body. A close friend and ally of Arroyo, Quezon Representative Danilo Suarez, confirmed that the President has started stem cell therapy, and that she told him that the stem cells she has been using did not come from lamb placenta, and was the less costly form of stem cell treatment. If you have a lot of health problems, you will try such things, Suarez said on Sunday. Suarez said he has even filed a resolution to investigate the practice of stem cell treatments in the country, as well as the claims being made about it, considering that it has been gaining popularity. The public needs … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on Arroyo undergoes 4th stem cell treatment

Neuralstem President And CEO To Present At The 2012 Rodman & Renshaw Annual Healthcare Conference

Posted: Published on September 10th, 2012

ROCKVILLE, Md., Sept. 10, 2012 /PRNewswire/ --Neuralstem, Inc. (NYSE MKT: CUR) announced that President and CEO Richard Garr will present at the 2012 Rodman & Renshaw Annual Healthcare Conference on Tuesday, September 11 at 2:00 p.m. EDT, at The Waldorf=Astoria, Starlight South. Garr will discuss the company's opportunities and advancements in neural stem cell therapy and pharmaceuticals. He will be providing an update on ongoing clinical trials, including the recently completed ALS Phase I, and an overview on future trials. To view the live webcast, visit Neuralstem's Investor Center at http://www.neuralstem.com , or: http://www.wsw.com/webcast/rrshq22/cur . (Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO ) The 2012 Rodman & Renshaw Annual Healthcare Conference is being held at The Waldorf=Astoria in New York City, September 9-11. For more information, see: http://www.rodm.com/conferences?id=176 . About Neuralstem Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem has recently completed an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's disease, and has been awarded orphan status designation by the FDA. In … Continue reading →

Posted in FDA Stem Cell Trials | Comments Off on Neuralstem President And CEO To Present At The 2012 Rodman & Renshaw Annual Healthcare Conference

Soon a stem cell jabs to end wrinkles

Posted: Published on September 10th, 2012

London, Sep 10: Ladies, you may not have to depend upon painful Botox injections and expensive cosmetic surgery for long to look young. A British firm is trialling a new natural method which involves injecting the patients own stem cells to restore skins youthful elasticity. Researchers believe they will spur the growth of new skin cells, called fibroblasts, which make the elastic ingredient collagen which is produced in large quantities when we are young, but declines as we age, the Daily Mail reported. The company Pharmacells, based in Glasgow, plans to begin clinical trials in 12 months, using stem cells harvested from a blood sample from the patients. They believe the procedure could be commercially available in just three years, potentially revolutionising the market for anti-ageing treatments. By using the bodys own cells, it is billed as a more natural approach to reducing the signs of ageing than Botox, a chemical which freezes the facial muscles to smooth wrinkles. The company has licensed the technology to harvest a new type of stem cell called a blastomere-like stem cell (CORR) which is found circulating in the blood. Like other types of stem cells, it is unspecialised and can develop into many … Continue reading →

Posted in Stem Cell Human Trials | Comments Off on Soon a stem cell jabs to end wrinkles

Mount Sinai Researchers Reveal a Chemotherapy-Resistant Cancer Stem Cell as the “Achilles' Heel” of Cancer

Posted: Published on September 10th, 2012

New York, NY (PRWEB) September 10, 2012 Scientists at Mount Sinai School of Medicine have discovered a subpopulation of cells that display cancer stem cell properties and resistance to chemotherapy, and participate in tumor progression. This breakthrough could lead to the development of new tests for early cancer diagnosis, prognostic tests, and innovative therapeutic strategies, as reported in Cancer Cell. Resistance to chemotherapy is a frequent and devastating phenomenon that occurs in cancer patients during certain treatments. Unfortunately, tumors that initially respond to chemotherapy eventually become resistant to it, contributing to tumor progression and death. The study reveals that these new cancer stem cells, which have not been differentiated into more specific cell types, are capable of multiplying despite being exposed to chemotherapy, while differentiated cells die. Led by Carlos Cordon-Cardo, MD, PhD, Chair of Pathology, and Josep Domingo-Domenech, MD, PhD, Assistant Professor of Pathology at Mount Sinai, the research team generated cellular models of drug resistance by treating prostate tumor cell lines with increasing doses of the common chemotherapy drugs, including docetaxel. They identified a cell population expressing markers of embryonic development. In addition, these cells displayed cancer stem cell functions, including the capacity to initiate tumor cell growth. … Continue reading →

Posted in Stem Cell Human Trials | Comments Off on Mount Sinai Researchers Reveal a Chemotherapy-Resistant Cancer Stem Cell as the “Achilles' Heel” of Cancer

Page 6,526«..1020..6,5256,5266,5276,528..6,5406,550..»